ArticleDiscover oncology2026
HPV status determines prognostic gene expression methylation and immune infiltration in head and neck squamous cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeHead and neck squamous cell carcinoma (HNSCC) continues to be a deadly cancer with heterogeneous molecular characteristics and poor survival outcomes, particularly in HPV- patients. This study aimed to identify key overexpressed genes that drive HNSCC progression, evaluate their prognostic value, and explore associations with HPV status, promoter methylation, and changes in the immune microenvironment.
methodsUsing bioinformatics tools (UALCAN, HPA, TISIDB), we analyzed TCGA-HNSC data to evaluate gene expression, survival correlations, HPV subgroup differences, promoter methylation, and immune infiltration patterns. Statistical significance was defined as p < 0.05.
resultsAmong the top 50 overexpressed genes in HNSCC, eight (LAMC2, CDKN2A, MFAP2, CTHRC1, CXCL13, FST, SPP1, PLAU) exhibited significant survival associations (p < 0.05). HPV- tumors demonstrated marked upregulation of LAMC2, CTHRC1, FST, SPP1, and PLAU, alongside downregulation of CDKN2A and CXCL13. Promoter hypomethylation in tumor tissues correlated with overexpression of LAMC2, CTHRC1, CXCL13, FST, SPP1, and PLAU, whereas CDKN2A showed hypermethylation. Immune infiltration analysis revealed strong correlations between these genes and immunosuppressive Tregs or cytotoxic T-cell depletion.
conclusionThis study identifies eight prognostic biomarkers in HNSCC linked to HPV-driven heterogeneity. These genes could be potential targets for therapy in combination with immunotherapy and epigenetic regulators, helping to overcome tumor resistance in HNSCC with different HPV status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.